评估 HLX10 + 化疗(卡铂-依托泊苷)在美国 ES-SCLC 患者中的疗效和安全性
HLX10 联合化疗(卡铂-依托泊苷)与 Atezolizumab 联合化疗在先前未治疗的美国广泛期小细胞肺癌 (ES-SCLC) 患者中进行比较的随机、开放标签研究
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
研究概览
地位
条件
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35223
- Alabama Oncology
-
-
Arizona
-
Goodyear、Arizona、美国、85338
- City of Hope - Phoenix
-
Tucson、Arizona、美国、85715
- Arizona Clinical Research Center (ACRC)
-
-
Arkansas
-
Springdale、Arkansas、美国、72762
- Highlands Oncology Group
-
-
California
-
Fountain Valley、California、美国、92708
- Compassionate Care Research Group
-
Fullerton、California、美国、92835
- Providence Medical Foundation
-
Glendale、California、美国、91204
- Los Angeles Cancer Network
-
Los Alamitos、California、美国、90720
- OPN - Oncology Physician Network
-
Los Angeles、California、美国、90034
- Kaiser Permanente Research (Southern California)
-
Sacramento、California、美国、95817
- UC Davis
-
-
Colorado
-
Colorado Springs、Colorado、美国、80920
- UCHealth Memorial Hospital North
-
Greeley、Colorado、美国、80631
- MD Anderson- North Colorado Medical Center
-
-
Florida
-
Brooksville、Florida、美国、34613
- Advanced Cancer Treatment Centers
-
Jacksonville、Florida、美国、32256
- Cancer Specialists North Florida
-
Miami、Florida、美国、33140
- Mount Sinai Comprehensive Cancer Center
-
Ocala、Florida、美国、34473
- Florida Cancer Affiliates- (Ocala Oncology - Main)
-
Orange City、Florida、美国、32763
- Mid Florida Hematology and Oncology Center
-
Plantation、Florida、美国、33322
- BRCR Global
-
Pompano Beach、Florida、美国、33064
- Napa Research
-
Tamarac、Florida、美国、33321
- Advanced Research
-
-
Hawaii
-
Honolulu、Hawaii、美国、96814
- Straub Benioff Medical Center
-
-
Illinois
-
Chicago、Illinois、美国、60099
- City of Hope- Chicago
-
Decatur、Illinois、美国、62526
- Cancer Center of Decatur
-
Tinley Park、Illinois、美国、60487
- Accellacare of Duly
-
-
Indiana
-
Dyer、Indiana、美国、46311
- Northwest Cancer Centers
-
-
Kansas
-
Wichita、Kansas、美国、67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington、Kentucky、美国、40503
- Baptist Health Lexington
-
Pikeville、Kentucky、美国、41501
- Pikeville Hospital
-
-
Louisiana
-
Alexandria、Louisiana、美国、71301
- CHRISTUS St. Frances Cabrini Cancer Center
-
Hammond、Louisiana、美国、70433
- Pontchartrain Cancer Center
-
-
Michigan
-
Southfield、Michigan、美国、48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Saint Paul、Minnesota、美国、55101
- Health Partners Cancer Center at Regions Hospital
-
-
Mississippi
-
Hattiesburg、Mississippi、美国、39401
- Hattiesburg Clinic Hematology/Oncology
-
-
Missouri
-
Kansas City、Missouri、美国、64132
- MidAmerica Division Inc., c/o Research Medical Center
-
Osage Beach、Missouri、美国、65065
- Lake Regional
-
-
Montana
-
Billings、Montana、美国、59102
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha、Nebraska、美国、68106
- University of Nebraska Medical Center
-
-
Nevada
-
Reno、Nevada、美国、89502
- Renown Health
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Freehold、New Jersey、美国、03756
- Regional Cancer Care Associates LLC RCCA
-
Neptune City、New Jersey、美国、07753
- Jersey Shore University Medical Center
-
-
New York
-
Elmhurst、New York、美国、11373
- Elmhurst (BRANY site)
-
Lake Success、New York、美国、11042
- Northwell Health
-
Stony Brook、New York、美国、11794
- Stony Brook Cancer Center
-
Williamsville、New York、美国、14221
- Great Lakes Cancer Care (Kaleida Health)
-
-
Ohio
-
Akron、Ohio、美国、44304
- Summa Health
-
Canton、Ohio、美国、44708
- Cleveland Clinic Mercy Hospital
-
Canton、Ohio、美国、44710
- Aultman Cancer Center
-
Cleveland、Ohio、美国、44106
- University Hospitals Cleveland Medical Center
-
Massillon、Ohio、美国、44646
- Tricounty Hematology and Oncology Associates
-
-
Pennsylvania
-
Wynnewood、Pennsylvania、美国、19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence、Rhode Island、美国、02908
- CharterCARE (Roger Williams)
-
-
Texas
-
Corpus Christi、Texas、美国、78404
- CHRISTUS Institute for Innovation & Advanced Clinical Care
-
Edinburg、Texas、美国、78539
- DHR Research
-
Houston、Texas、美国、77090
- Millennium Research and Clinical Development
-
Kingwood、Texas、美国、77339
- Lumi Research
-
Lubbock、Texas、美国、79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler、Texas、美国、75701
- The University of Texas Health Science Center at Tyler/HOPE Cancer Center
-
-
Utah
-
Salt Lake City、Utah、美国、84106
- Utah Cancer Specialists
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute
-
-
Washington
-
Olympia、Washington、美国、98502
- American Oncology Network Vista Oncology Division
-
Tacoma、Washington、美国、98405
- Northwest Medical Specialties, PLLC
-
-
West Virginia
-
Morgantown、West Virginia、美国、26505
- West Virginia University Cancer Institute
-
-
Wisconsin
-
Madison、Wisconsin、美国、53792
- University of Wisconsin Carbone Cancer Center
-
Milwaukee、Wisconsin、美国、53226
- Froedtert Hospital- Medical College of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Voluntary participation in clinical studies.
Male or female aged ≥ 18 years at the time of signing the ICF.
Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
No prior systemic therapy for ES-SCLC.
Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.
Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.
Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
An ECOG PS score of 0 or 1.
An expected survival ≥ 12 weeks.
Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.
Normal major organ functions.
Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion Criteria:
Histologically or cytologically confirmed mixed SCLC.
Other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
Patients who are preparing for or have received an organ or bone marrow transplant.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
Patients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.
Class III to IV cardiac insufficiency according to NYHA classification.
Subject has uncontrolled or symptomatic hypercalcemia.
Subject with peripheral neuropathy ≥ Grade 2 by CTCAE.
Human immunodeficiency virus (HIV) infection, positive test for HIV antibody.
Active or latent pulmonary tuberculosis.
Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
Hepatitis B or Hepatitis C or Hepatitis B and C co-infection.
Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
Have received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
The subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
Known history of severe allergy to any monoclonal antibody.
Known hypersensitivity to carboplatin or etoposide.
Pregnant or lactating females.
Active use of psychotropics abuse or drug abuse.
In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Serplulimab + chemotherapy
Serplulimab + chemotherapy (carboplatin-etoposide) |
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics |
|
有源比较器:Atezolizumab + chemotherapy
Atezolizumab + chemotherapy (carboplatin-etoposide) |
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
OS
大体时间:A period from randomization through death regardless of causality (approximately up to 24 months).
|
Overall assessment |
A period from randomization through death regardless of causality (approximately up to 24 months).
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective response rate (ORR)
大体时间:approximately up to 14 months
|
Objective response rate (ORR) (assessed by independent radiology review committee [IRRC] and the investigator based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) |
approximately up to 14 months
|
|
Progression-free survival (PFS)
大体时间:approximately up to 24 months
|
Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1) |
approximately up to 24 months
|
|
PFS2
大体时间:Approximately up to 24 months
|
PFS2 (assessed by the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Duration of response (DOR)
大体时间:Approximately up to 24 months
|
Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Adverse events
大体时间:approximately up to 24 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. |
approximately up to 24 months
|
|
Observed concentration of HLX10 in serum
大体时间:Approximately up to 24 months
|
Observed concentration of HLX10 in serum |
Approximately up to 24 months
|
|
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
大体时间:Approximately up to 24 months
|
The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation. |
Approximately up to 24 months
|
|
HLX10 anti-drug antibody (ADA)
大体时间:Approximately up to 24 months
|
HLX10 anti-drug antibody (ADA) |
Approximately up to 24 months
|
|
Neutralizing antibody (NAb)
大体时间:Approximately up to 24 months
|
Neutralizing antibody (NAb) positive rate |
Approximately up to 24 months
|
|
Quality of life assessment
大体时间:Approximately up to 24 months
|
Lung cancer Quality of life assessment |
Approximately up to 24 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Exploratory Endpoint
大体时间:Approximately up to 24 months
|
Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker |
Approximately up to 24 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- ASTRIDE (HLX10-005-SCLC301-E)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.